leadf
logo-loader
viewAmryt Pharma PLC

Amryt Pharma reports record Q3 2020 results, delivering 19% year on year growth

Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results.

The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide.

Wiley talks through these results which show 19% YoY revenue growth in the quarter to $49.3m, with a rise in full year revenue guidance to $180m - $182m.

Quick facts: Amryt Pharma PLC

Price: 205 GBX

AIM:AMYT
Market: AIM
Market Cap: £366.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma boss 'really pleased' with FY results, on 18.5% increase in...

Amryt Pharma PLC (LON:AMYT) (NASDAQ:AMYT) CEO Joey Wiley tells Proactive it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year. Wiley says the biopharma company, which acquires, develops and commercializes novel...

2 days, 16 hours ago

2 min read